Adrian Newman-Tancredi

List of Publications by Year in Descending Order

170 papers	7,385 citations	48 h-index	78 g-index
184 ext. papers	8,131 ext. citations	5.2 avg, IF	5.78 L-index

#	Paper	IF	Citations
170	Dissecting the contribution of 5-HT auto- and heteroreceptors in sucrose overconsumption in mice.. *Biomedicine and Pharmacotherapy*, **2022**, 148, 112699	7.5	0
169	Biased 5-HT receptor agonists F13714 and NLX-101 differentially affect pattern separation and neuronal plasticity in rats after acute and chronic treatment.. *Molecular and Cellular Neurosciences*, **2022**, 120, 103719	4.8	0
168	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. *Pharmacological Reviews*, **2021**, 73, 310-520	22.5	48
167	The selective 5-HT receptor agonist NLX-112 displays anxiolytic-like activity in mice. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2021**, 395, 149	3.4	1
166	Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline. *Behavioural Pharmacology*, **2021**, 32, 652-659	2.4	1
165	[F]F13640, a 5-HT Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. *Frontiers in Neuroscience*, **2021**, 15, 622423	5.1	2
164	Identification of the 5-HT serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease. *Neurobiology of Disease*, **2021**, 152, 105278	7.5	3
163	The selective 5-HT receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress. *Psychopharmacology*, **2021**, 238, 2249-2260	4.7	5
162	Translating biased agonists from molecules to medications: Serotonin 5-HT receptor functional selectivity for CNS disorders. *Pharmacology & Therapeutics*, **2021**, 107937	13.9	6
161	The 5-HT receptor as a serotonergic target for neuroprotection in cerebral ischemia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 109, 110210	5.5	3
160	Towards in vivo imaging of functionally active 5-HT receptors in schizophrenia: concepts and challenges. *Translational Psychiatry*, **2021**, 11, 22	8.6	3
159	Perspectives for therapy of treatment-resistant depression. *British Journal of Pharmacology*, **2021**,	8.6	5
158	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson's Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. *Journal of Parkinson's Disease*, **2021**, 11, 1257-1269	5.3	1
157	NLX-101, a cortical 5-HT receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition. *Brain Research*, **2021**, 1765, 147493	3.7	5
156	The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. *Neuropharmacology*, **2020**, 167, 107997	5.5	15
155	Activation of 5-HT postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 99, 109832	5.5	19
154	Pharmacological MRI to investigate the functional selectivity of 5-HT receptor biased agonists. *Neuropharmacology*, **2020**, 172, 107867	5.5	6

153	The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. *Parkinsonism and Related Disorders*, **2020**, 78, 151-157	3.6	7
152	Discovery of Novel pERK1/2- or Arrestin-Preferring 5-HT Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. *Journal of Medicinal Chemistry*, **2020**, 63, 10946-10971	8.3	6
151	F-F13640 PET imaging of functional receptors in humans. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 220-221	8.8	13
150	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT Receptor-Biased Agonists with Robust Antidepressant-like Activity. *Journal of Medicinal Chemistry*, **2019**, 62, 2750-2771	8.3	14
149	Enhanced aggressive phenotype of Tph2 knockout rats is associated with diminished 5-HT receptor sensitivity. *Neuropharmacology*, **2019**, 153, 134-141	5.5	6
148	Serotonin 5-HT Receptor Biased Agonists Display Differential Anxiolytic Activity in a Rat Social Interaction Model. *ACS Chemical Neuroscience*, **2019**, 10, 3101-3107	5.7	11
147	Bell-shaped agonist activation of 5-HT receptor-coupled G G-proteins: Receptor density-dependent switch in receptor signaling. *Cellular Signalling*, **2019**, 63, 109383	4.9	6
146	Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model. *Journal of Psychopharmacology*, **2019**, 33, 1456-1466	4.6	14
145	From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery. *Current Topics in Medicinal Chemistry*, **2019**, 19, 2393-2420	3	16
144	Serotonin 5-HT Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats. *ACS Chemical Neuroscience*, **2019**, 10, 3108-3119	5.7	11
143	Activation of somatodendritic 5-HT autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test. *Psychopharmacology*, **2019**, 236, 1171-1185	4.7	5
142	Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT receptor biased agonists. *Experimental Neurology*, **2018**, 302, 155-168	5.7	15
141	Activity of Serotonin 5-HT Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties. *ACS Chemical Neuroscience*, **2018**, 9, 1040-1050	5.7	32
140	F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT receptor agonist for PET neuroimaging. *Brain Structure and Function*, **2018**, 223, 2973-2988	4	17
139	NLX-112, a highly selective 5-HT receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT receptors, respectively. *Brain Research*, **2018**, 1688, 1-7	3.7	17
138	Effects of the Serotonin 5-HT Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats. *Neurochemical Research*, **2018**, 43, 1035-1046	4.6	9
137	In vivo biased agonism at 5-HT receptors: characterisation by simultaneous PET/MR imaging. *Neuropsychopharmacology*, **2018**, 43, 2310-2319	8.7	16
136	NLX-112, a highly selective 5-HT receptor agonist: Effects on body temperature and plasma corticosterone levels in rats. *Pharmacology Biochemistry and Behavior*, **2018**, 165, 56-62	3.9	3

135	Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT receptor agonist. *Journal of Pharmacy and Pharmacology*, **2017**, 69, 1178-1190	4.8	22
134	Characterizing the differential roles of striatal 5-HT auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. *Experimental Neurology*, **2017**, 292, 168-178	5.7	30
133	Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT receptor selective agonist, NLX-112 in mouse models of pain. *Neuropharmacology*, **2017**, 125, 181-188	5.5	25
132	Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	18
131	Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study. *Scientific Reports*, **2016**, 6, 26633	4.9	37
130	Anti-aggressive effects of the selective high-efficacy biased 5-HT1A receptor agonists F15599 and F13714 in male WTG rats. *Psychopharmacology*, **2016**, 233, 937-47	4.7	17
129	The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements. *Neuropharmacology*, **2016**, 105, 651-660	5.5	26
128	Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals. *Neuropharmacology*, **2016**, 109, 88-95	5.5	27
127	The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. *Neuropharmacology*, **2015** , 97, 306-11	5.5	33
126	NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. *Experimental Neurology*, **2015**, 271, 335-50	5.7	51
125	Activity of serotonin 5-HT(1A) receptor biased agonists in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. *Neuropharmacology*, **2015**, 93, 52-67	5.5	55
124	Divergent effects of the biased 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task. *British Journal of Pharmacology*, **2015**, 172, 2532-43	8.6	30
123	Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. *Current Pharmaceutical Design*, **2015**, 21, 3725-31	3.3	22
122	5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. *Psychopharmacology*, **2014**, 231, 623-36	4.7	117
121	ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility. *British Journal of Pharmacology*, **2014**, 171, 973-84	8.6	18
120	Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2014**, 387, 545-57	3.4	27
119	Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. *Neurobiology of Learning and Memory*, **2014**, 110, 72-80	3.1	58
118	Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists. *Frontiers in Physiology*, **2014**, 5, 205	4.6	24

117	A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease. *CNS Neuroscience and Therapeutics*, **2014**, 20, 930-4	6.8	18
116	Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. *Neuropharmacology*, **2013**, 70, 338-47	5.5	142
115	In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. *Psychopharmacology*, **2012**, 221, 261-72	4.7	36
114	S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 750-64	4.7	12
113	Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging. *Journal of Nuclear Medicine*, **2012**, 53, 969-76	8.9	20
112	Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model. *Behavioural Pharmacology*, **2011**, 22, 599-606	2.4	9
111	Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. *European Journal of Pharmacology*, **2011**, 655, 46-51	5.3	44
110	Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents. *European Journal of Pharmacology*, **2011**, 672, 83-7	5.3	11
109	Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference. *Cellular Signalling*, **2011**, 23, 58-64	4.9	10
108	Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. *Psychopharmacology*, **2011**, 216, 451-73	4.7	119
107	Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 339, 2-8	4.7	40
106	Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. *Neuropsychiatry*, **2011**, 1, 149-164	1.8	69
105	Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. *British Journal of Pharmacology*, **2010**, 160, 1929-40	8.6	78
104	The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. *Journal of Neurochemistry*, **2010**, 114, 1323-32	6	37
103	Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. *Neuroscience Research*, **2010**, 66, 135-40	2.9	31
102	F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. *European Neuropsychopharmacology*, **2010**, 20, 641-54	1.2	67
101	F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. *International Journal of Neuropsychopharmacology*, **2010**, 13, 1285-98	5.8	75
100	[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 594-605	8.8	37

99	The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. *Current Opinion in Investigational Drugs*, **2010**, 11, 802-12		70
98	The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine. *Pharmacology Biochemistry and Behavior*, **2009**, 92, 363-9	3.9	22
97	F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. *European Journal of Pharmacology*, **2009**, 607, 74-83	5.3	8
96	F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. *European Journal of Pharmacology*, **2009**, 620, 27-35	5.3	24
95	Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. *British Journal of Pharmacology*, **2009**, 156, 338-53	8.6	101
94	5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. *British Journal of Pharmacology*, **2009**, 158, 232-42	8.6	22
93	Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. *Behavioural Brain Research*, **2009**, 203, 288-95	3.4	11
92	Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies. *Behavioural Brain Research*, **2009**, 205, 360-6	3.4	95
91	Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. *Behavioural Pharmacology*, **2009**, 20, 303-11	2.4	23
90	Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. *European Journal of Pharmacology*, **2008**, 581, 37-46	5.3	22
89	The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. *European Journal of Pharmacology*, **2008**, 592, 160-6	5.3	38
88	Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. *European Journal of Pharmacology*, **2008**, 594, 32-8	5.3	61
87	Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds. *European Journal of Pharmacology*, **2008**, 597, 34-8	5.3	16
86	S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I.	4.7	51
85	Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. *International Journal of Neuropsychopharmacology*, **2008**, 11, 293-307	5.8	22
84	Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. *Behavioural Pharmacology*, **2008**, 19, 145-52	2.4	46
83	High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. *Journal of Medicinal Chemistry*, **2007**, 50, 5024-33	8.3	55
82	F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. *British Journal of Pharmacology*, **2007**, 151, 237-52	8.6	35

81	F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. *British Journal of Pharmacology*, **2007**, 151, 253-65	8.6	37
80	F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. *British Journal of Pharmacology*, **2007**, 151, 266-77	8.6	47
79	WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. *European Journal of Pharmacology*, **2007**, 574, 15-9	5.3	35
78	F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, 2007, 375, 241-50	3.4	8
77	Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2007**, 376, 93-105	3.4	21
76	Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. *Psychopharmacology*, **2007**, 193, 45-54	4.7	21
75	Native rat hippocampal 5-HT1A receptors show constitutive activity. *Molecular Pharmacology*, **2007**, 71, 638-43	4.3	34
74	Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. *Behavioural Pharmacology*, **2007**, 18, 103-18	2.4	42
73	Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. *Neuropharmacology*, **2007**, 52, 1106-13	5.5	31
72	Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. *Journal of Medicinal Chemistry*, **2007**, 50, 865-76	8.3	35
71	Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. *Current Opinion in Investigational Drugs*, **2007**, 8, 539-54		26
70	In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2006**, 373, 441-50	3.4	32
69	Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. *European Journal of Pharmacology*, **2006**, 534, 63-70	5.3	58
68	Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. *European Journal of Pharmacology*, **2006**, 535, 135-44	5.3	66
67	Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. *Neuropsychopharmacology*, **2006**, 31, 1869-79	8.7	78
66	Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. *Neuropsychopharmacology*, **2006**, 31, 1900-9	8.7	55
65	Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. *British Journal of Pharmacology*, **2006**, 149, 170-8	8.6	52
64	Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. *Pharmacology*, **2005**, 75, 63-8	2.3	7

63	Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. *Neuropharmacology*, **2005**, 49, 135-43	5.5	69
62	Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. *Neuropharmacology*, **2005**, 49, 963-76	5.5	19
61	Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. *Neuropharmacology*, **2005**, 49, 996-1006	5.5	107
60	Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. *International Journal of Neuropsychopharmacology*, **2005**, 8, 341-56	5.8	106
59	Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. *Brain Research*, **2005**, 1043, 32-41	3.7	48
58	Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. *Psychopharmacology*, **2005**, 177, 373-80	4.7	13
57	Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1034-42	4.7	24
56	Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 265-72	4.7	108
55	S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 903-20	4.7	26
54	The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 306, 954-64	4.7	414
53	Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2003**, 368, 188-99	3.4	25
52	h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. *British Journal of Pharmacology*, **2003**, 138, 1077-84	8.6	17
51	Differential ligand efficacy at h5-HT1A receptor-coupled G-protein subtypes: a commentary. *International Congress Series*, **2003**, 1249, 101-117		3
50	Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization. *Pharmacology Biochemistry and Behavior*, **2002**, 71, 589-98	3.9	13
49	Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors. *Cellular Signalling*, **2002**, 14, 829-37	4.9	24
48	Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2002**, 365, 242-52	3.4	71
47	Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. *Psychopharmacology*, **2002**, 162, 168-77	4.7	38
46	Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. *Molecular Pharmacology*, **2002**, 62, 578-89	4.3	98

45	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 791-804	4.7	361
44	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 815-22	4.7	159
43	Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. *Molecular Pharmacology*, **2002**, 62, 590-601	4.3	62
42	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 805-14	4.7	151
41	Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. *Journal of Medicinal Chemistry*, **2002**, 45, 165-76	8.3	27
40	The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. *Psychopharmacology*, **2001**, 156, 58-62	4.7	103
39	Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635. *British Journal of Pharmacology*, **2001**, 132, 518-24	8.6	23
38	Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. *Brain Research*, **2001**, 920, 41-54	3.7	25
37	Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase. *European Journal of Pharmacology*, **2001**, 424, 13-7	5.3	13
36	Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. *European Journal of Pharmacology*, **2001**, 428, 177-84	5.3	21
35	Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. *Neuropsychopharmacology*, **2001**, 25, 410-22	8.7	31
34	Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. *Journal of Medicinal Chemistry*, **2001**, 44, 787-805	8.3	38
33	Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms. *Neuropharmacology*, **2001**, 40, 57-64	5.5	23
32	Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons. *Journal of Neuroscience Research*, **2000**, 59, 740-9	4.4	10
31	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. *Synapse*, **2000**, 35, 79-95	2.4	141
30	Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. *Synapse*, **2000**, 36, 205-21	2.4	264
29	Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. *European Journal of Neuroscience*, **2000**, 12, 1079-95	3.5	132
28	The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. *European Journal of Pharmacology*, **2000**, 394, 47-50	5.3	19

27	[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2000**, 361, 569-72	3.4	14
26	An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **2000**, 361, 221-3	3.4	7
25	[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum. *Neuropharmacology*, **2000**, 39, 1111-3	5.5	8
24	Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. *Molecular Pharmacology*, **2000**, 58, 1042-9	4.3	38
23	Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. *Molecular Pharmacology*, **1999**, 56, 1025-30	4.3	99
22	Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2059-64	2.9	61
21	Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. *European Journal of Neuroscience*, **1999**, 11, 4419-32	3.5	112
20	Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1999**, 359, 447-53	3.4	17
19	The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study. *European Journal of Pharmacology*, **1999**, 384, 111-21	5.3	14
18	Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. *Neuropsychopharmacology*, **1999**, 21, 61S-67S	8.7	18
17	Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535. *Annals of the New York Academy of Sciences*, **1998**, 861, 263-4	6.5	5
16	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. *European Journal of Pharmacology*, **1998**, 355, 245-56	5.3	180
15	Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. *Neuropsychopharmacology*, **1998**, 18, 395-8	8.7	51
14	Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1998**, 357, 205-17	3.4	26
13	Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. *Neuroscience*, **1998**, 84, 413-29	3.9	179
12	Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. *Neuropharmacology*, **1998**, 37, 769-80	5.5	12
11	Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine. *European Journal of Pharmacology*, **1997**, 327, 247-56	5.3	15
10	Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. *European Journal of Pharmacology*, **1997**, 319, 379-83	5.3	54

9	Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry. *Neuropharmacology*, **1997**, 36, 451-9	5.5	81
8	Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. *British Journal of Pharmacology*, **1997**, 120, 737-9	8.6	73
7	Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1997**, 355, 682-8	3.4	41
6	Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. *Neuropharmacology*, **1996**, 35, 119-21	5.5	89
5	S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors. *European Journal of Pharmacology*, **1996**, 307, 107-11	5.3	40
4	[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors. *Neuropharmacology*, **1995**, 34, 1693-6	5.5	8
3	Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. *European Journal of Pharmacology*, **1995**, 280, 225-9	5.3	17
2	Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms. *Biochemical Pharmacology*, **1993**, 45, 1003-9	6	49
1	Pharmacological characterisation of the 5-HT1A serotonin receptor using the agonist [3H]8-OH-DPAT, and the antagonist [3H]spiperone. *Biochemical Society Transactions*, **1992**, 20, 145S	5.1	6